Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price […]
HC Wainwright reissued their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $60.00 price target on the stock. A number of other equities analysts also recently weighed in on the company. JMP Securities reiterated a market […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock. A number of other research firms have also commented on CRNX. Morgan Stanley increased […]
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $5,307,931.20 in Stock etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $46.00 to $48.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 7.50% from the stock’s previous close. […]